수두증 션트 시장(2025-2035년) : 기회, 성장 촉진요인, 산업 동향 분석, 예측

The Global Hydrocephalus Shunt Market was valued at USD 295.7 million in 2024 and is estimated to grow at a CAGR of 3.5% to reach USD 424.1 million by 2035. This growth is primarily driven by the rising number of cases related to hydrocephalus, frequently linked to traumatic brain injuries and brain tumors. As the prevalence of these conditions increases, so does the demand for reliable treatment solutions. Advances in medical technology have also significantly impacted this market. Developments such as adjustable pressure shunt valves, anti-siphon systems, and the use of biocompatible materials are enhancing patient outcomes while minimizing complications.

The introduction of smart shunt systems, which allow real-time cerebrospinal fluid monitoring and flow regulation, is further reducing the need for surgical revisions. Major manufacturers like Integra LifeSciences Holdings, Medtronic, and B. Braun continue to invest in research and product innovation to meet evolving clinical needs. Hydrocephalus shunts are designed to divert excess cerebrospinal fluid from the brain's ventricles to other areas of the body for absorption, preventing elevated intracranial pressure and potential neurological damage. The medical community increasingly relies on these systems for both pediatric and adult hydrocephalus management, further reinforcing their importance in modern neurosurgical practice.

The hydrocephalus valves segment led the market in 2024, capturing 85.1%. This growth stems from the increasing frequency of hydrocephalus cases and a surge in related surgeries worldwide. Innovative valve designs offering programmable control and antimicrobial properties are playing a crucial role in reducing complications and revision rates. Non-invasive pressure adjustments have improved patient management, while the rising number of elderly individuals and higher birth rates in many regions contribute to the growing hydrocephalus patient population. Surgeons and healthcare providers are increasingly choosing valves that offer long-term durability and personalized control over CSF drainage, especially in specialized medical facilities.

Ventriculoperitoneal shunts accounted for USD 196.7 million in 2024. VP shunting continues to be the preferred approach for treating hydrocephalus due to its cost-effectiveness, surgical adaptability, and consistent success across various clinical settings. Compared to alternative treatments, VP shunts offer a more affordable and widely adopted solution, particularly in pediatric care and regions with limited healthcare budgets. The rising number of cases involving congenital hydrocephalus in children and the growing recognition of normal pressure hydrocephalus among older adults are fueling the increased deployment of VP systems across hospitals globally.

United States Hydrocephalus Shunt Market is expected to reach USD 146.3 million by 2034. With over a million individuals affected nationwide and tens of thousands of shunt placements performed annually, the condition remains a significant medical challenge. Market expansion is supported by innovations in programmable shunts, improved device designs, and better cerebrospinal fluid regulation methods. These developments not only improve treatment outcomes but also decrease the frequency of revision procedures. Additionally, sustained investment in R&D and advanced product launches are expected to elevate the market's trajectory across the region.

Leading market participants in the Hydrocephalus Shunt Space include Medtronic, B. Braun, Integra LifeSciences Holdings, Sophysa, Luciole Medical, DESU, HLL Lifecare, Hpbio, Kaneka Medix, G. Surgiwear, Wellong Instruments Co., and Neutral Pharma. Companies operating in the hydrocephalus shunt market are focusing on innovation, R&D investment, and global expansion to reinforce their market positions.

Key strategies include developing advanced programmable valves, antimicrobial shunt coatings, and smart shunt systems with real-time monitoring features. These innovations aim to minimize revision surgeries and enhance patient safety. Firms are also entering strategic collaborations with hospitals and neurosurgery centers to improve clinical feedback loops and co-develop next-gen devices. Regulatory approvals and strong distribution networks across emerging economies are other priorities, enabling companies to tap into high-growth regions.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional/country
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis
• 2.2 Key market trends
  • 2.2.1 Regional trends
  • 2.2.2 Product type trends
  • 2.2.3 Procedure type trends
  • 2.2.4 Age group trends
  • 2.2.5 End use trends

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of congenital hydrocephalus
    • 3.2.1.2 Growing awareness towards surgical treatment of hydrocephalus
    • 3.2.1.3 Availability of reimbursement coverage for hydrocephalus treatments
    • 3.2.1.4 Increasing geriatric population
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Lack of infrastructure for performing complex neurosurgeries in emerging countries
    • 3.2.2.2 High cost associated to hydrocephalus shunt surgery and follow-up care
  • 3.2.3 Market opportunities
    • 3.2.3.1 Technological Advancements and Smart Shunt Innovation
    • 3.2.3.2 Integration of Artificial Intelligence (AI) and Advanced Diagnostics
• 3.3 Growth potential analysis
  • 3.3.1 By product type
  • 3.3.2 By procedure type
  • 3.3.3 By age group
  • 3.3.4 By end use
• 3.4 Regulatory landscape
  • 3.4.1 U.S.
  • 3.4.2 Europe
• 3.5 Technology and innovation landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis
• 3.8 Future market trends
• 3.9 Patent analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
  • 4.1.1 Medtronic
  • 4.1.2 Integra LifeSciences Holdings
  • 4.1.3 B. Braun
• 4.2 Competitive market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 – 2035 ($ Mn)

• 5.1 Key trends
• 5.2 Hydrocephalus valves
  • 5.2.1 Adjusted pressure valves
  • 5.2.2 Fixed Pressure valves
• 5.3 Hydrocephalus catheter
  • 5.3.1 Standard catheters
  • 5.3.2 Antibiotic catheters

Chapter 6 Market Estimates and Forecast, By Procedure Type, 2021 – 2035 ($ Mn)

• 6.1 Key trends
• 6.2 Ventriculoperitoneal
• 6.3 Lumboperitoneal
• 6.4 Ventriculoatrial
• 6.5 Ventriculopleural

Chapter 7 Market Estimates and Forecast, By Age Group, 2021 – 2035 ($ Mn)

• 7.1 Key trends
• 7.2 Pediatric
• 7.3 Adult

Chapter 8 Market Estimates and Forecast, By End Use, 2021 – 2035 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals
• 8.3 Ambulatory surgical centers

Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2035 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Italy
  • 9.3.5 Spain
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 B. Braun
• 10.2 DESU
• 10.3 G. Surgiwear
• 10.4 HLL Lifecare
• 10.5 Hpbio
• 10.6 Integra LifeSciences Holdings
• 10.7 Kaneka Medix
• 10.8 Luciole Medical
• 10.9 Medtronic
• 10.10 Neutral Pharma
• 10.11 Sophysa
• 10.12 Wellong Instruments Co.